SOLARA ACTIVE PHARMA SCIENCES Financial Statement Analysis
|
||
|
The Revenues of SOLARA ACTIVE PHARMA SCIENCES have increased by 13.83% YoY .
The Earnings Per Share (EPS) of SOLARA ACTIVE PHARMA SCIENCES has decreased by Negative YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
SOLARA ACTIVE PHARMA SCIENCES Last 5 Annual Financial Results
[BOM: 541540|NSE : SOLARA]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹1,444 Cr | ₹1,268 Cr | ₹1,617 Cr | ₹1,322 Cr | ₹1,387 Cr |
| Expenses | ₹1,310 Cr | ₹1,188 Cr | ₹1,231 Cr | ₹1,062 Cr | ₹1,166 Cr |
| Operating Profit (Excl OI) | ₹134 Cr | ₹80 Cr | ₹386 Cr | ₹259 Cr | ₹221 Cr |
| Other Income | ₹23 Cr | ₹20 Cr | ₹29 Cr | ₹28 Cr | ₹12 Cr |
| Interest | ₹90 Cr | ₹75 Cr | ₹84 Cr | ₹78 Cr | ₹82 Cr |
| Depreciation | ₹111 Cr | ₹112 Cr | ₹109 Cr | ₹94 Cr | ₹83 Cr |
| Profit Before Tax | ₹-45 Cr | ₹-91 Cr | ₹222 Cr | ₹115 Cr | ₹68 Cr |
| Profit After Tax | ₹-22 Cr | ₹-58 Cr | ₹221 Cr | ₹115 Cr | ₹67 Cr |
| Consolidated Net Profit | ₹-22 Cr | ₹-58 Cr | ₹221 Cr | ₹115 Cr | ₹60 Cr |
| Earnings Per Share (Rs) | ₹-157.61 | ₹-6.16 | ₹-16.15 | ₹61.62 | ₹42.69 |
| PAT Margin (%) | -43.99 | -1.54 | -4.60 | 13.69 | 8.66 |
| ROE(%) | -46.64 | -1.47 | -3.75 | 17.23 | 12.48 |
| ROCE(%) | -17.29 | 1.79 | -0.67 | 15.34 | 11.73 |
| Total Debt/Equity(x) | 1.07 | 0.67 | 0.67 | 0.38 | 0.72 |
Key Financials |
||
| Market Cap | : | ₹ 3,045.9 Cr |
| Revenue (TTM) | : | ₹ 1,258.6 Cr |
| Net Profit(TTM) | : | ₹ -536.2 Cr |
| EPS (TTM) | : | ₹ -111.5 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SOLARA ACTIVE PHARMA SCIENCES | -9.9% | -15.2% | 72.4% |
| SUN PHARMACEUTICAL INDUSTRIES | -5.8% | -3.2% | 35.1% |
| CIPLA | -3.9% | -0.5% | 13.9% |
| DR REDDYS LABORATORIES | -1.2% | 7.1% | 17.8% |
| ZYDUS LIFESCIENCES | -2.7% | -0.1% | 40.9% |
| DIVIS LABORATORIES | -2.8% | -3.6% | 44.7% |
| MANKIND PHARMA | -11.2% | -2.3% | 33.6% |
| TORRENT PHARMACEUTICALS | -4.8% | -2.7% | 40.1% |
| LUPIN | -8.6% | 1.8% | 56.9% |
SOLARA ACTIVE PHARMA SCIENCES Revenues
[BOM: 541540|NSE : SOLARA]
| Y-o-Y | 13.83 % |
| 5 Yr CAGR | 1.01 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,444 Cr | 13.83 | |
| Mar2023 | ₹1,268 Cr | -21.56 | |
| Mar2022 | ₹1,617 Cr | 22.33 | |
| Mar2021 | ₹1,322 Cr | -4.68 | |
| Mar2020 | ₹1,387 Cr | - | |
SOLARA ACTIVE PHARMA SCIENCES Operating Profit
[BOM: 541540|NSE : SOLARA]
| Y-o-Y | 67.41 % |
| 5 Yr CAGR | -11.76 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹134 Cr | 67.41 | |
| Mar2023 | ₹80 Cr | -79.28 | |
| Mar2022 | ₹386 Cr | 48.73 | |
| Mar2021 | ₹259 Cr | 17.49 | |
| Mar2020 | ₹221 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 46.91 % |
| 5 Yr CAGR | -12.65 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 9.27% | 46.91 | |
| Mar2023 | 6.31% | -73.57 | |
| Mar2022 | 23.87% | 21.60 | |
| Mar2021 | 19.63% | 23.30 | |
| Mar2020 | 15.92% | - | |
SOLARA ACTIVE PHARMA SCIENCES Profit After Tax
[BOM: 541540|NSE : SOLARA]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹-22 Cr | Negative | |
| Mar2023 | ₹-58 Cr | Negative | |
| Mar2022 | ₹221 Cr | 93.18 | |
| Mar2021 | ₹115 Cr | 92.59 | |
| Mar2020 | ₹60 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | -43.99 % | Negative | |
| Mar2023 | -1.54 % | Negative | |
| Mar2022 | -4.6 % | Negative | |
| Mar2021 | 13.69 % | 58.08 | |
| Mar2020 | 8.66 % | - | |
SOLARA ACTIVE PHARMA SCIENCES Earnings Per Share (EPS)
[BOM: 541540|NSE : SOLARA]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹-158 | Negative | |
| Mar2023 | ₹-6.16 | Negative | |
| Mar2022 | ₹-16 | Negative | |
| Mar2021 | ₹62 | 44.34 | |
| Mar2020 | ₹43 | - | |
SOLARA ACTIVE PHARMA SCIENCES Return on Capital Employed (ROCE)
[BOM: 541540|NSE : SOLARA]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | -17.29% | Negative | |
| Mar2023 | 1.79% | Positive | |
| Mar2022 | -0.67% | Negative | |
| Mar2021 | 15.34% | 30.78 | |
| Mar2020 | 11.73% | - | |
SOLARA ACTIVE PHARMA SCIENCES Share Price vs Sensex
| Current Share Price | : | ₹633.3 |
| Current MarketCap | : | ₹ 3,045.9 Cr |
| Updated EOD on | : | Jan 13,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SOLARA ACTIVE PHARMA SCIENCES | -9.9% |
-15.2% |
72.4% |
| SENSEX | -2.1% |
-6.4% |
7% |
SOLARA ACTIVE PHARMA SCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
| S&P BSE HEALTHCARE | -5.3% | -4.2% | 32% |
| S&P BSE SMALL CAP | -7% | -12.4% | 15.8% |
| S&P BSE MIDSMALLCAP | -7.2% | -12.1% | 14.7% |
No NSE index found
You may also like the below Video Courses
FAQ about SOLARA ACTIVE PHARMA SCIENCES Financials
How the annual revenues of SOLARA ACTIVE PHARMA SCIENCES have changed ?
The Revenues of SOLARA ACTIVE PHARMA SCIENCES have increased by 13.83% YoY .
How the Earnings per Share (EPS) of SOLARA ACTIVE PHARMA SCIENCES have changed?
The Earnings Per Share (EPS) of SOLARA ACTIVE PHARMA SCIENCES has decreased by Negative YoY .
Check out Intrinsic Value of Peers of SOLARA ACTIVE PHARMA SCIENCES
Compare Stock Analytics of Peers of SOLARA ACTIVE PHARMA SCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
